Skandinaviska Enskilda Banken (SEB)’s Vir Biotechnology VIR Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-123,500	Closed	-$3.03M	–	994
2023 Q2	$3.03M	Sell	123,500 -228,000	-65%	-$5.73M	0.02%	461
2023 Q1	$8.18M	Sell	351,500 -92,100	-21%	-$2.36M	0.06%	293
2022 Q4	$11.2M	Buy	+443,600	New	+$10.9M	0.08%	235
2020 Q4	–	Sell	-220	Closed	-$8K	–	1163
2020 Q3	$8K	Hold	220	–	–	﹤0.01%	1009
2020 Q2	$9K	Hold	220	–	–	﹤0.01%	1043
2020 Q1	$8K	Buy	+220	New	+$5.91K	﹤0.01%	904

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s VIR Position: Q3 2023 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 123,500 shares — an estimated $3.03M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in VIR in Q1 2020 and held it in 6 quarters. The position peaked at $11.2M in Q4 2022. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

Skandinaviska Enskilda Banken (SEB) reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 123,500 Vir Biotechnology shares in Q3 2023, an estimated $3.03M.
Skandinaviska Enskilda Banken (SEB) first reported a position in Vir Biotechnology in Q1 2020 and held it in 6 quarters.
Skandinaviska Enskilda Banken (SEB)'s Vir Biotechnology position peaked at $11.2M in Q4 2022.
214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2023, filed 9 Nov 2023.